Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality

British Journal of Haematology - Tập 178 Số 2 - Trang 319-326 - 2017
Ann Brunson1, Amy Q. Lei1, Aaron S. Rosenberg1, Richard H. White2, Theresa H.M. Keegan1, Ted Wun1,3,4
1Center for Oncology and Hematology Outcomes Research and Training (COHORT), Division of Hematology Oncology, UC Davis School of Medicine, Sacramento, CA, USA
2Division of General Internal Medicine, UC Davis School of Medicine, Sacramento, CA, USA
3Section of Hematology Oncology, VA Northern California Health Care System, Sacramento, CA, USA
4UC Davis Clinical and Translational Sciences Center, Sacramento, CA, USA

Tóm tắt

SummaryPrevious reports show increased incidence of venous thromboembolism [VTE, deep‐vein thrombosis (DVT) and pulmonary embolus (PE)] in sickle cell disease (SCD) patients but did not account for frequency of hospitalization. We determined the incidence of VTE in a SCD cohort versus matched controls. For SCD patients, risk factors for incident VTE, recurrence and the impact on mortality were also determined. Among 6237 patients with SCD, 696 patients (11·2%) developed incident‐VTE: 358 (51·6%) had PE (±DVT); 179 (25·7%) had lower‐extremity DVT only and 158 (22·7%) had upper‐extremity DVT. By 40 years of age, the cumulative incidence of VTE was 17·1% for severe SCD patients (hospitalized ≥3 times a year) versus 8·0% for the matched asthma controls. Amongst SCD patients, women (Hazard ratio [HR] = 1·22; 95% confidence interval [CI]: 1·05–1·43) and those with severe disease (HR = 2·86; 95% CI: 2·42–3·37) had an increased risk of VTE. Five‐year recurrence was 36·8% in patients with severe SCD. VTE was associated with increased risk of death (HR = 2·88, 95% CI: 2·35–3·52). In this population‐based study, the incidence of VTE was higher in SCD patients than matched controls and was associated with increased mortality. The high incidence of recurrent VTE in patients with severe SCD suggests that extended anticoagulation may be indicated.

Từ khóa


Tài liệu tham khảo

10.1182/blood-2006-11-057604

10.2105/AJPH.2014.302172

10.1002/pbc.25431

10.1056/NEJM199505183322001

10.1016/j.jacc.2011.03.031

10.1016/j.amepre.2009.12.022

10.1007/s11239-006-5572-y

10.1038/nrcardio.2015.83

10.7326/M14-1275

10.1111/jth.13336

10.1016/j.chest.2015.11.026

10.1183/09031936.00150312

10.1016/j.amjmed.2012.12.016

10.1111/jth.12744

National Center for Health Statistics. (2014)ICD‐9‐CM: International Classification of Diseases 9th Revision Clinical Modification 6th ed. Available at:https://www.cdc.gov/nchs/icd/icd9cm.htm

10.1111/j.1538-7836.2012.04697.x

10.1002/pbc.25208

10.1056/NEJM199107043250103

Singer D.E., 2009, The net clinical benefit of warfarin anticoagulation in atrial fibrillation, Annals of Internal Medicine, 151, 297, 10.7326/0003-4819-151-5-200909010-00003

10.1016/j.amjmed.2006.08.015

10.1161/01.CIR.0000078468.11849.66

10.1016/j.thromres.2010.03.009

10.1016/j.thromres.2016.03.003

Thông tin
Thông tin xuất bản

British Journal of Haematology

Tập 178 Số 2

319-326

Thông tin tác giả